SCHEMBL25145116

SCHEMBL25145116

CNc1ccc(C(=O)N2CCCC(NC(=O)OC(C)(C)C)C2)cc1N

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ NPC1L1 Q9UHC9 2/20 0.48
▸ BTK Q06187 2/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ PADI4 Q9UM07 4/20 0.45
▸ USP30 Q70CQ3 2/20 0.45
▸ MAP4K4 O95819 2/20 0.44
▸ PARP1 P09874 1/20 0.43
▸ NAMPT P43490 1/20 0.42
▸ BRD4 O60885 1/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30325458 1.00 CA1 (0.51) CA1CA2NPC1L1BTKHDAC3
SCHEMBL16841169 1.00 CA1 (0.51) CA1CA2NPC1L1BTKHDAC3
SCHEMBL18976645 0.91 CA1 (0.54) CA1CA2NPC1L1BTKHDAC3
SCHEMBL18247703 0.86 KMT2A (0.47) KMT2A
SCHEMBL18192381 0.86 KMT2A (0.47) KMT2A
SCHEMBL29979011 0.85 CA1 (0.52) CA1CA2NPC1L1BTKHDAC3
SCHEMBL16844216 0.85 CA1 (0.48) CA1CA2NPC1L1BTKPADI4
SCHEMBL16841185 0.85 CA1 (0.48) CA1CA2NPC1L1BTKPADI4
SCHEMBL30325417 0.85 CA1 (0.48) CA1CA2NPC1L1BTKPADI4
SCHEMBL21295091 0.83 CA1 (0.52) CA1CA2NPC1L1BTKHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298003-B1 BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2023-04-19 — — EP disclosed
CN-107849015-B Benzimidazole derivatives as PAD4 inhibitors 葛兰素知识产权发展有限公司 2021-03-19 — — CN disclosed
Send feedback